Icon Legend

This session is not in your schedule.

This session is in your schedule. Click again to remove it.

Presentation Icons

Live Streamed

On Demand

Back

327 Views

Z2. COVID-19 Infection prevention

Poster Session: COVID-19: Infection Prevention

(P-1960) Safety and Pharmacokinetics of Long-acting SARS-CoV-2 Antibodies Tixagevimab/Cilgavimab (AZD7442) are Consistent after Repeat Dosing: Results from the PROVENT Substudy

Saturday, October 19, 2024

12:15 PM – 1:30 PM US PT

Location: Halls JK

Co-Author(s)

AU

Andrew Ustianowski, MD, PhD

North Manchester General Hospital
Manchester, England, United Kingdom

Co-Author(s)

ML

Myron J. Levin, MD

Professor
University of Colorado Denver School of Medicine
Aurora, Colorado, United States
SD

Stéphane De Wit, MD

CHU St-Pierre
Brussels, Brussels Hoofdstedelijk Gewest, Belgium
OL

Odile Launay, MD, PhD

Head of I Reivac, French vaccine research network
Université Paris Cité; Inserm F-CRIN, I-REIVAC; Assistance Publique Hôpitaux de Paris
Paris, Ile-de-France, France
HB

Hilde Bollen, MD

Anima Research Center
Alken, Limburg, Belgium
TR

Tommy Rampling, MBChB, DPhil

University College London Hospitals NHS Foundation Trust
London, England, United Kingdom
JS

James G. Sullivan, MD

Parkway Medical Center
Birmingham, Alabama, United States
MV

Mark Vishnepolsky, MD, MBA

Kidney Specialists of Southern Nevada; DaVita Clinical Research
Las Vegas, Nevada, United States
PW

Priyantha Wijewardane, MD

Baptist Health Center for Clinical Research
Little Rock, Arkansas, United States
AS

Audrey Sharbaugh, PhD

AstraZeneca
Durham, North Carolina, United States
RB

Rohini Beavon, PhD

AstraZeneca
Cambridge, England, United Kingdom
JT

Jesse Thissen, MSc

AstraZeneca
Cambridge, England, United Kingdom
LH

Lauren Hirao, PhD

AstraZeneca
Gaithersburg, Maryland, United States
VD

Vitalina Dzutseva, MD, PhD

AstraZeneca
Gaithersburg, Maryland, United States
SS

Seth Seegobin, PhD

AstraZeneca
Cambridge, England, United Kingdom
Katie Streicher, PhD (she/her/hers)

Head of Translational Medicine, Vaccines and Immune Therapies
AstraZeneca
Gaithersburg, Maryland, United States
AK

Alexandre Kiazand, MD

AstraZeneca
Gaithersburg, Maryland, United States
Mark T. Esser, PhD

Vice President of Vaccines and Immune Therapies early R&D
AstraZeneca
Gaithersburg, MD, United States
Taylor Cohen, PhD

Global Project Lead
AstraZeneca
Gaithersburg, Maryland, United States

Presenting Author(s)

Lee-Jah Chang, MD (he/him/his)

Vice President, Clinical Development, Vaccines and Immune Therapies
AstraZeneca
Gaithersburg, Maryland, United States

Co-Author(s)

JP

John L. Perez, MD

AstraZeneca
Gaithersburg, Maryland, United States